Excalipoint Therapeutics
Excalipoint Therapeutics
Developing next-generation T-cell engager therapies for cancer and autoimmune diseases.
About
No comments yet. Be the first to share your take.
What does Excalipoint Therapeutics do?
Excalipoint Therapeutics is a biotechnology company focused on developing next-generation T-cell engager (TCE) therapies. The company leverages proprietary technology platforms, including TOPAbody, T-Cell Immune Shield, and TCE Probody, to create highly differentiated treatments for solid tumors and autoimmune diseases.
How much funding has Excalipoint Therapeutics raised?
Excalipoint Therapeutics has raised a total of $69M in funding. The most recent round on record is Seed.
Where is Excalipoint Therapeutics headquartered?
Excalipoint Therapeutics is headquartered in Shanghai, China.
When was Excalipoint Therapeutics founded?
Excalipoint Therapeutics was founded in 2025.
What industry does Excalipoint Therapeutics operate in?
Excalipoint Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Oncology, Immunology.
What is Excalipoint Therapeutics's revenue?
StartupHub estimates Excalipoint Therapeutics's annual revenue at $8.4M (range $2.2M to $28.8M, 37% confidence), based on comparable companies in the sector.
What is Excalipoint Therapeutics's valuation?
StartupHub estimates Excalipoint Therapeutics's effective valuation at $259.7M (range $171.8M to $412.2M, 24% confidence), based on comparable companies in the sector.